CVC in talks over acquisition of Recordati
The Recordati family, the controlling shareholder of Italian pharmaceutical company Recordati, has confirmed that it is holding talks to sell its majority stake in the business to private equity firm CVC Capital Partners.
According to press reports, the proposed deal is valued at around €3bn.
Press reports suggested that CVC held talks with Recordati over a possible takeover in recent months but that the deal was put on hold in May due to concerns about the country's political uncertainty. The negotiations were then revived in June, after the formation of a new Italian government.
The Recordati family, via its holding Fimei, controls a 51.7% stake in the company.
Fimei CEO Alberto Recordati said in a statement that while the talks are proceeding, there are still several obstacles to overcome that could jeopardise the outcome of the negotiations.
Press reports mentioned disagreements between the Recordati family members regarding the future of the company, and the decision to fully exit the business is still controversial.
Recordati, which is listed on the Italian stock exchange, has a market capitalisation of around €7bn and a net debt of €484.6m.
The company recorded EBITDA of €454.7m in 2017, up 22.5% on the previous year, from revenues of €1.3bn.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds









